Pembrolizumab-associated Neuronopathy with Improved Lower Limb Somatosensory Evoked Potential After Intravenous Methylprednisolone Treatment: A Case Report
-
- Tachiyama Keisuke
- Department of Clinical Neuroscience and Therapeutics, Hiroshima University Hospital, Japan
-
- Naito Hiroyuki
- Department of Clinical Neuroscience and Therapeutics, Hiroshima University Hospital, Japan
-
- Nakamori Masahiro
- Department of Clinical Neuroscience and Therapeutics, Hiroshima University Hospital, Japan
-
- Aoki Shiro
- Department of Clinical Neuroscience and Therapeutics, Hiroshima University Hospital, Japan
-
- Maruyama Hirofumi
- Department of Clinical Neuroscience and Therapeutics, Hiroshima University Hospital, Japan
書誌事項
- タイトル別名
-
- Pembrolizumab-associated Neuronopathy with Improved Lower Limb Somatosensory Evoked Potential After Intravenous Methylprednisolone Treatment
説明
<p>Cases of neuronopathy associated with immune checkpoint inhibitors (ICIs) have rarely been reported. We herein report a case of ICI-associated neuronopathy. A 54-year-old man underwent chemotherapy for right maxillary sinus cancer. Two months after pembrolizumab treatment, diarrhea, worsening of abnormal sensations, and severe ataxia of the lower limbs were observed. Somatosensory evoked potentials (SEPs) with tibial nerve stimulation showed disappearance of the N21 waveform. A colonic biopsy suggested ICI-associated colitis. Based on these findings, the patient was diagnosed with ICI-associated neuronopathy. Clinical symptoms and SEP findings improved markedly after two courses of intravenous methylprednisolone. </p>
収録刊行物
-
- Internal Medicine
-
Internal Medicine 64 (9), 1408-1411, 2025-05-01
一般社団法人 日本内科学会
